Huatang DK Invited to 'Future Healthcare 100 Summit', Accelerating the Commercialization of Ophthalmic Innovations in China

June 15,Huatang DachangInvited to attend the "6th Future Healthcare Top 100 Conference," the companyMr. Tian Bingshi, General Manager of the Business Channel Management Divisionat the “Ophthalmology Industry Innovation Forum”《Capital Influx, Heated Market: How to Accelerate the Commercialization of Ophthalmic Products》Delivered a keynote speech titled “...” and, together with experts and scholars in the ophthalmology industry, explored the development trends of the ophthalmology sector empowered by capital and innovative technologies, while sharing Huatang Dachang’s exemplary practices in accelerating the growth of the eye health industry.

As an annual summit exploring trends in China’s healthcare industry, the “Top 100 Future Healthcare Conference” has been successfully held five times since 2016, attracting nearly 20,000 industry professionals. It has become the largest and most information-rich event in China’s healthcare innovation sector for integrating industry and capital.

As a leader in ophthalmic commercialization services, Huatang Dachang has been dedicated for 16 years to providing end-to-end commercial solutions for high-value international medical device products. With extensive experience serving leading multinational clients in the ophthalmology sector, the company continues to pioneer and drive innovative commercialization processes. Honored by this invitation, Huatang Dachang looks forward to engaging with industry experts and authoritative teams to gain deeper insights into market dynamics, share industry intelligence, and jointly explore future development and innovative technologies in ophthalmology, thereby broadening strategic perspectives to empower industrial progress with commercial value.

Policy Support Drives High-Quality Development of China’s Ophthalmology Industry

At the forum, Mr. Tian Bingshi, General Manager of the Business Channel Management Division at Huatang Dachang, conducted a focused analysis of development trends in the ophthalmology industry from four dimensions: policy, economy, society, and technological innovation within the sector.

As eye health becomes a key component of the “Healthy China” initiative, and driven by the deepening healthcare reforms that bolster the ophthalmic medical industry, China’s ophthalmology market is exhibiting a trend of “significant growth within a specialized sector.” The Regulations on the Administration of Medical Institutions, released in April 2022, highlight state support for the development of medical institutions and encourage their establishment through diverse models. Under the encouragement and support of multiple national policies, the environment for privately run medical practices in China has been continuously optimized, leading to their rapid expansion. Furthermore, the Action Plan for Bright Vision in Myopia Prevention and Control among Children and Adolescents (2021–2025), jointly issued by the Ministry of Education and 14 other departments, emphasizes strategies for early monitoring, detection, and warning regarding children’s eye care and vision. This indicates that greater attention will be devoted to myopia prevention, control, and scientific correction among children and adolescents in the future.

Increased government policy support will drive comprehensive development in the ophthalmology field and industry. The Chinese ophthalmology market, particularly private specialized eye hospitals and hospital chains, has entered a phase of rapid growth, with the scale of private eye hospitals expanding at an annual rate of approximately 20%. The output value of major private ophthalmology chains grew by 25% in 2021. Meanwhile, influenced by factors such as population aging, remote work, home-based learning, and frequent use of electronic devices, the incidence of ophthalmic diseases is showing a trend of affecting younger populations and growing rapidly. Public awareness and understanding of eye health are gradually strengthening, leading to increasing demand for ophthalmic services.

The market size and investment value of the ophthalmology industry are expanding rapidly at a growth rate exceeding the industry average. This hotly contested sector, presenting both opportunities and challenges, is increasingly favored by capital investors; domestic financing surpassed RMB 8 billion in 2021, while private ophthalmology chains have experienced rapid development. Given the substantial future market potential of the ophthalmology industry, it is crucial for enterprises seeking to efficiently execute market layout and promotion in China to partner with an experienced collaborator who possesses a deep understanding of the complex medical device market.

A Century of Progress: Huatang Dachang Leads the Commercialization of High-Value Medical Devices in China

Huatang DKSH traces its origins to the China operations of DKSH, a century-old Swiss enterprise. In recent years, the company has achieved rapid growth with the support of its shareholder, Warburg Pincus. Today, Huatang DKSH has become a leading commercial solutions provider in China, dedicated to serving global brands in the high-value medical device sector. It delivers end-to-end, professional commercialization services, enhancing the accessibility of innovative global medical devices in China through exceptional commercialization solutions.

Huatang Dachang has accumulated extensive experience in serving global brands with cross-border operations. It has established long-term partnerships with numerous clients, covering high-value medical device brands across multiple medical specialties, including ophthalmology, in vitro diagnostics (IVD), orthopedics, cardiology, neurology, obstetrics and gynecology, vascular surgery, endocrinology, pulmonology, and high-value medical consumables. Its clients include globally leading brands such as Alcon, MicroVention, Illumina, Smith & Nephew, Roche, Abbott, and Procter & Gamble.

Since launching commercial services in the ophthalmology sector in 2006, Warton Dachang has accumulated extensive experience and resources in establishing private chain partnerships, helping products rapidly seize first-mover market advantages, efficiently building a nationwide distribution network, and leveraging streamlined processes and informatization services. The company is fully committed to accelerating the commercialization of ophthalmic care in China.

Deep Expertise, One-Stop Solutions: Huatang Dachang Delivers Comprehensive Services for Global High-Value Medical Devices

Given the ophthalmology industry’s substantial import demand for overseas high-tech products, technical equipment, and high-value consumables, traditional distribution models characterized by high costs and multi-party negotiations are no longer viable from a product circulation perspective. There is an urgent need for an end-to-end commercialization service in this sector.

Huatang Dachang’s unique advantage lies in providing end-to-end commercialization solutions for high-value medical device products worldwide, covering product registration, import and export, warehousing and distribution, channel management, inventory and after-sales management, as well as nationwide distribution channels. Meanwhile, Huatang Dachang also offers a comprehensive digital platform that supports the entire business process, capable of developing customized applications tailored to specific business scenarios. This meets clients’ holistic data management needs and enhances their operational efficiency and scalability.

● Digital Platform for the Entire Business Process

Huatang Dachang’s End-to-End Digital Business Platform leverages specialized, customized one-stop intelligent services to streamline business processes for upstream and downstream partners in the ophthalmology commercialization ecosystem. Centered on the SAP system, the platform enables efficient operations through intelligent, visualized, and predictive capabilities. The end-to-end digital business platform covers all stages of the entire process, including import/export declaration and customs clearance, coding and traceability, cross-border procurement, warehousing and distribution, inventory management, consignment sales, returns and exchanges, channel management, marketing campaigns, tender and bidding management, rebate agreement management, product flow tracking, as well as credit and collections. By integrating with multiple stakeholders—including upstream brand owners, downstream distributors, hospitals, retail outlets, as well as external systems such as Customs, the National Medical Products Administration (NMPA) regulatory platform, and the State Taxation Administration platform—the platform facilitates seamless data exchange and achieves comprehensive information sharing across the entire ecosystem.

● Superior Distributor Management Capability

As a one-stop national commercial solutions provider platform, W&T DACHANG boasts an extensive network of high-quality downstream distributors, establishing a nationwide integrated distribution network for ophthalmology clients and delivering comprehensive distributor management services. Currently, W&T DACHANG manages over 500 local distributors with broad distribution channels across China, covering more than 1,700 public hospitals (including Grade A tertiary hospitals), nearly 900 private hospitals, and 10,000 pharmacies in all provinces, municipalities, and autonomous regions. This enables seamless integration between upstream and downstream partners, facilitating the rapid market entry and penetration of pharmaceutical brands in China.

Huatang Dachang possesses two exceptional commercial service capabilities in the ophthalmology sector: the “VMI Front-Loaded Virtual Warehouse” and the “Direct Supply Service for Private Hospitals.” By leveraging localized management teams, rigorous VMI consignment management processes, and an intelligent VMI consignment management platform, Huatang Dachang capitalizes on the advantages of its VMI Front-Loaded Virtual Warehouse—namely, variety, speed, scalability, and cost-efficiency. This approach addresses critical pain points such as the timeliness of invoicing for VMI consignment products, expiration date management, and inventory security. Through these combined measures, the company maximizes product commercialization, particularly accelerating the market entry of new products. Furthermore, it enhances customers’ capital turnover efficiency and strengthens channel partnership stickiness. Huatang Dachang’s superior agile services in its VMI Front-Loaded Virtual Warehouse have earned high recognition from clients and partners alike.

Furthermore, Huatang Dachang’s direct-supply service for private hospitals is designed to address the business characteristics of centralized group management and decentralized hospital collaborations by providing a multi-dimensional commercial operations management system. Serving over 600 private hospitals, including Aier Eye Hospital and Huaxia Eye Hospital, Huatang Dachang aligns manufacturers’ strategies, private healthcare groups’ strategies, and the operational needs of affiliated hospitals. By flexibly matching resources on the basis of standardized management, it assists high-value medical device brands in rapidly expanding their business within private healthcare groups, delivers high-quality, end-to-end supply chain services to these groups and their affiliated hospitals, and achieves multi-party business synergy.

Looking ahead, Huatang Dachang will continue to partner with global manufacturers of high-value medical devices to jointly promote the high-quality development of China’s healthcare market, empower the commercialization process of China’s ophthalmology industry, increase the market share of leading products, further enhance efficiency and reduce distribution costs, and actively advance the accessibility of global medical innovations.